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BACKGROUND: Advanced biliary tract carcinoma has a very poor prognosis, with chemotherapy being the mainstay of treatment.
Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-b, B-Raf, and C-Raf, has shown to be active in preclinical models of
cholangiocarcinoma.
METHODS: We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma. Sorafenib was
administered at a dose of 400mg twice a day. The primary end point was the disease control rate at 12 weeks.
RESULTS: A total of 46 patients were treated. In all, 26 (56%) had received chemotherapy earlier, and 36 patients completed at least
45 days of treatment. In intention-to-treat analysis, the objective response was 2% and the disease control rate at 12 weeks was
32.6%. Progression-free survival (PFS) was 2.3 months (range: 0–12 months), and the median overall survival was 4.4 months
(range: 0–22 months). Performance status was significantly related to PFS: median PFS values for ECOG 0 and 1 were 5.7 and
2.1 months, respectively (P¼0.0002). The most common toxicities were skin rash (35%) and fatigue (33%), requiring a dose
reduction in 22% of patients.
CONCLUSIONS: Sorafenib as a single agent has a low activity in cholangiocarcinoma. Patients having a good performance status have
a better PFS. The toxicity profile is manageable.
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Adenocarcinoma of the gallbladder and cholangiocarcinoma
account for 4 and 3% of all gastrointestinal cancers, respectively
(Fong et al, 2001, p 1178). The incidence is 1–2 per 100000 in the
United States and Europe, and increases to 87 per 100000 in
Southeast Asia (De Groen et al, 1999). These are highly fatal
malignancies, with 1- and 2-year survival rates of 25 and 13%,
respectively (Fong et al, 1996; Lazcano-Ponce et al, 2001).
Surgery represents the only curative option; however, only
B25% of patients with gallbladder carcinoma are radically
resectable, with a 5-year survival rate of B40%; patients with
cholangiocarcinoma have an even worse prognosis, with a 5-year
survival rate of 5–10%. Patients with unresectable disease receive
palliative chemotherapy. Many agents including fluoropyri-
midines, gemcitabine, cisplatin/oxaliplatin, mitomycin C, doxo-
rubicin, docetaxel, and irinotecan have been tested with response
rates ranging from 10 to 40% (Berardi et al, 2006; Hezel and
Zhu, 2008). However, despite its limited activity and morbidity,
chemotherapy remains the mainstay of treatment for most
patients and the combination of gemcitabine plus cisplatin is
recommended as the standard of care. (Eckel and Schmid, 2007;
Valle et al, 2009).
Molecular alterations such as disruption of the MAPK pathway
and activating RAS and B-Raf mutations have been described in
these tumours, and these molecular abnormalities may constitute a
target for new biological agents (Tannapfel et al, 2003). However,
biliary tract carcinoma usually shows hypovascularity, suggesting
that angiogenesis pathways may have a minor role in the
pathogenesis and progression of disease (Kawahara et al, 1998).
Sorafenib, an orally available multikinase inhibitor of VEGFR-
2/-3, PDGFR-b, B-Raf, C-Raf, FLT-3, and RET, has shown an
anti-tumour activity in preclinical models of breast, colon, and
pancreatic cancer, as well as in a phase I clinical trial in solid
tumours (Wilhelm et al, 2004; Beeram et al, 2005; Strumberg et al,
2005) and in a phase II trial in metastatic thyroid cancer (Kloos
et al, 2009). On the basis of randomised clinical trials, sorafenib
has been approved for the treatment of renal cell carcinoma and
hepatocellular carcinoma (Escudier et al, 2007; Llovet et al, 2008a).
More recently, Huether et al (2007) have demonstrated that
sorafenib can potently suppress the growth of human cholangio-
carcinoma cells in a preclinical model.
On these premises, we have designed a phase II clinical trial
of a single-agent sorafenib in patients with advanced biliary
tract carcinoma. Moreover, we planned to perform biomarker
analysis including the BRAF mutation and VEGFR-2 expression.
These analyses are still ongoing and will be presented in future
research.
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Patient selection
Patients were eligible if they had a pathologically proven diagnosis
of advanced and unresectable cholangiocarcinoma, extrahepatic
biliary duct carcinoma, or gallbladder carcinoma, an ECOG
performance status 0–1, measurable disease, as well as adequate
liver and renal function tests. A total serum bilirubin level up to
3.0mg per 100ml was allowed. Advanced disease was defined as
primary tumours or relapsed disease not amenable for radical
surgery or metastatic disease. Earlier treatments including surgery,
locoregional treatment, and systemic therapy were allowed as
well. Patients were required to sign an informed consent, and the
Local Ethics Committee of the Province of Modena approved the
study.
Study design
This was a phase II single-arm open-label non-randomised
multicentre trial. The primary objective was to evaluate the
activity, defined as the disease control rate at 12 weeks, of
sorafenib as a single agent in patients with advanced cholangio-
carcinoma. Disease control rate was defined as the percentage
of patients without disease progression (complete response,
partial response, stable disease) and still on treatment at 12 weeks.
Secondary objectives included progression-free survival (PFS),
overall survival (OS), and tolerability.
Progression-free survival was defined as the time from the first
day of administration of the study drug to disease progression or
death for toxicity or disease progression.
Overall survival was defined as the time from the first day of
study medication administration to death or last contact.
Treatment plan
Sorafenib was administered at a fixed dose of 400mg twice a day
continuously in a 4-week cycle until disease progression,
unacceptable toxicity, physician’s decision to remove the patient,
or withdrawal of patient consent.
Doses were delayed or reduced in case of haematological or non-
haematological toxicity graded according to the NCI Common
Toxicity Criteria Version 2.0. The sorafenib predefined dose level
reductions were level  1: 200mg po q 12h; and level  2: 200mg
po per day. In case of G1 toxicity or first occurrence of G2 toxicity
lasting o7 days, no dose modification or delay was planned. For
G2 toxicity lasting 47 days, for the second and third occurrence of
G2 or G3 toxicity, a treatment delay until resolution to G0–1 and
a dose reduction to level  1 were planned. After the fourth
occurrence, treatment was discontinued. In case of G3 non-
haematological or G4 haematological toxicity at first and second
occurrence, treatment was delayed until toxicity resolution to
G0–1, and 1 level dose reduction was planned. After the third
occurrence, treatment was discontinued. In case of G4 toxicity,
treatment was delayed until toxicity resolution, and a dose
reduction of 2 dose levels was planned. If, after a 3-week delay,
the patient did not recover to G0–1, treatment was discontinued.
Assessment of disease
Baseline evaluation included medical history, physical examina-
tion, and tumour assessment with computed tomography (CT) or
magnetic resonance (MRI) within 28 days of study entry; CT/MRI
scans of the brain and bone scans were performed if clinically
indicated. Tumour response was evaluated every 12 weeks
(3 cycles) with the same imaging techniques (CT or MRI) used
at baseline. In case of complete, partial response, or stable disease,
a reassessment of disease was performed using the same technique
(CT or MRI) after 4–6 weeks to confirm the response.
Statistical analysis
The primary end point of the trial was the disease control rate
(CRþPRþSD according to the RECIST criteria) at 12 weeks.
Sample size was calculated according to the Simon double-stage
design test. We assumed as a non-interest hypothesis, a disease
control rate p0.15 and, as result of interest, a disease control rate
X0.35. According to our hypothesis, the study required 32
subjects. If the number of patients with disease control was X8
or more, the hypothesis that Pp0.150 would have been rejected
with a target error rate of 0.100 and an actual error rate of 0.096. If
the number of events was p7 or less, the hypothesis that PX0.350
would have been rejected with a target error rate of 0.100 and an
actual error rate of 0.082.
RESULTS
Patient characteristics
From August 2006 to December 2007, 46 patients with recurrent
or metastatic biliary tract adenocarcinoma were enrolled into this
phase II trial; enrolment was expanded to 46 patients because
14 patients discontinued the treatment within 45 days from study
entry. The main patient characteristics were as follows: median age
66 years (37–80); 32 cholangiocarcinomas (69.6%), 14 gallbladder
carcinomas (30.4%), and all patients were not amenable to surgery.
A total of 26 patients had received chemotherapy earlier, including
gemcitabine, platinum compound, and fluoropyrimidines
(Table 1).
Toxicity
Toxicity was evaluated on the entire group of 46 patients.
There were no treatment-related deaths. In all, 10 patients
(21.7%) had a dose reduction: 1 to 75%; 9 to 50%. These dose
reductions were due to G3 toxicity: skin rash in six patients;
HFS in two patients; and fatigue and mucositis in two patients.
Eight patients (17.4%) discontinued the treatment because of
toxicity: three patients for prolonged (43 weeks) G3 hand–foot
syndrome, one patient for prolonged G3 skin rash, one for G3
diarrhoea, one for G3 cardiac ischaemia, one for prolonged G3
fatigue, and one for prolonged G2 thrombocytopaenia.
The most common event was skin rash that occurred in
16 patients (35%), which was classified as G1–2 in 9 patients
(20%) and as G3 in 7 patients (15%). Eight patients (17%)
presented hand–foot syndrome: G1–2 in three patients (37.5%)
and G3 in five patients (11%). Liver dysfunction was observed in
28% of patients, mostly due to cancer progression. However, G1–2
and G3 drug-related liver toxicity was observed in two (4.3%) and
one patient (2.2%), respectively. Other G3 toxicities included
fatigue and diarrhoea in five patients (11%) and in one patient
(2%), respectively. Three patients experienced deep venous
thrombosis (DVT) and two had pulmonary embolism. One
patient taking corticosteroids for concomitant chronic obstructive
pulmonary disease and paraneoplastic fever experienced a G4
gastrointestinal bleeding. Haematological toxicity was mild:
G1–2 thrombocytopaenia was observed in 13 patients (28%) and
G3 anaemia in 1 patient (2.2%) Table 2 shows the adverse events
that are considered to be possibly drug related.
Outcome
According to the intention-to-treat analysis, an analysis for
the primary end point (DCR) was performed on the entire group
of patients (46 patients): 1 patient achieved a partial response
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s(2.2%) and 14 patients (30.4%) achieved a stable disease for a
disease control rate of 32.6% at 12 weeks. The disease control rates
in the chemonaive and pretreated patients were 30 and 35%,
respectively. In all, 14 patients received o45 days of treatment
(median: 22 days; range: 5–37): 1 patient for low compliance,
5 for early toxicity, and 8 for very early progression. However,
for the intent-to-treat analysis, the 14 patients were considered as
having disease progression. The median duration of disease
control in the group of patients receiving at least 12 weeks of
treatment was 6 months (3.5–11.9).
According to the intention-to-treat analysis, the median PFS
was 2.3 months (range: 0–12 months) (Figure 1) and median
OS was 4.4 months (range: 0–22 months) (Figure 2). Neither
disease site (intra vs extrahepatic) nor previous treatments were
significantly related to PFS. On the contrary, PFS was significantly
related to performance status: median PFS was 5.7 for ECOG 0 and
2.1 months for ECOG 1 (P¼0.0002). This advantage was also
observed in OS: median OS was 8.8 months (range: 3.2–13.3) for
ECOG 0 and 3.5 months (0.53–14.0) for ECOG 1 (P¼0.0008)
(Figure 3).
DISCUSSION
Very few treatment options are available for advanced biliary
tract carcinoma, and the prognosis of these patients is very
poor. Recently, a pooled analysis of 112 clinical trials of
chemotherapy in advanced biliary tract carcinoma showed a
tumour response rate and disease control rate of 22.6 and 57.3%,
respectively, whereas the median time to progression and OS were
4.1 and 8.1 months, respectively (Eckel and Schmid, 2007).
Recently, the combination of gemcitabine and cisplatin has been
reported to be significantly superior than gemcitabine alone in
patients with advanced or metastatic advanced biliary tract cancer
(Furuse et al, 2009; Valle et al, 2009).
Owing to the molecular alterations described in cholangiocarci-
nomas, we designed a phase II trial to test the activity of sorafenib
as a single agent in advanced and metastatic biliary tract
carcinoma.
Single-agent sorafenib has very low activity (measured as an
objective response) in renal cell and hepatocellular carcinoma;
however, it can significantly prolong PFS and OS in both tumour
types. Therefore, we have identified the disease control rate at
Table 2 Toxicity (n¼46)
G1–G2 (%) G3–G4 (%) Total (%)
Skin rash 9 (20) 7 (15) 16 (35)
Hand–foot syndrome 3 (6) 5 (11) 8 (17)
Gastrointestinal 18 (39) 7 (15) 25 (54)
Diarrhoea 3 (6) 1 (2) 4 (8)
Stomatitis 4 (8) 0 (0) 4 (8)
Nausea/vomiting 4 (8) 0 (0) 0 (8)
Liver enzyme 2 (4) 1 (2) 3 (6)
Haematological 13 (28) 1 (2) 14 (30)
Anaemia 2 (4) 1 (2) 3 (6)
Trombocytopaenia 11 (24) 0 (0) 11 (24)
Neutropaenia 0 (0) 0 (0) 0 (0)
Febrile neutropaenia 0 (0) 0 (0) 0 (0)
Systemic symptoms 10 (22) 5 (11) 2 (33)
Fatigue 10 (22) 5 (11) 15 (33)
Infection 0 (0) 1 (2) 1(2)
Cardiovascular 1 (2) 3 (6) 4 (8)
Deep vein thrombosis 1 (2) 0 (0) 1 (2)
Pulmonary embolism 0 (0) 2 (4) 2 (4)
Cardiac ischaemia 0 (0) 1 (2) 1 (2)
Coagulation (DIC) 1 (2) 0 (0) 1 (2)
Haemorrhage/bleeding 0 (0) 1 (2) 1 (2)
Metabolic/laboratory 5 (11) 1 (2) 6 (13)
Abbreviation: DIC¼disseminated intravascular coagulation.
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Figure 1 Progression-free survival (N¼46).
Table 1 Patient characteristics
Number of patients (n¼46)
Median age, years 66 (range: 37–80)
Gender n (%)
Male 20 (44)
Female 26 (56)
ECOG performance status
ECOG 0 15 (33)
ECOG 1 31 (67)
Site
Gallbladder 14 (30)
Extrahepatic 5 (10)
Intrahepatic 27 (60)
TNM stage
II 2 (4)
III 7 (15)
IV 37 (81)
Previous treatments
Surgery 28 (61)
Radical 19 (41)
Palliative/biopsy 9 (20)
Chemotherapy lines 26 (56)
1 6 (13)
2 11 (24)
3 7 (15)
43 2 (4)
Radiotherapy 5 (10)
Stereotactic 1 (2)
Palliative 4 (8)
Local treatments 4 (8)
Hyperthermy 2 (4)
RF 1 (2)
TACE/RF 1 (2)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; TNM¼tumour–
node–metastasis; TACE¼transcatheter arterial chemoembolisation; RF¼radio
frequency ablation.
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s12 weeks as the primary end point of our trial. This is a suitable
end point in oncology when a non-cytotoxic agent is used and a
low objective response rate, along with a high stable disease rate,
is expected (Llovet et al, 2008b; Adjei et al, 2009).
At the intention-to-treat analysis, the response rate and the
stable disease rate were 2.2 and 30.4%, respectively, with a disease
control rate of 32.6%. Unfortunately, the median time to disease
progression and OS were disappointing: 2.3 and 4.4 months,
respectively. However, patients with an ECOG 0 performance
status had a median PFS and a median OS that were significantly
longer than did patients with an ECOG 1 performance status: 5.7 vs
2.1 months and 8.8 vs 3.5 months, respectively. To our knowledge,
very few data on sorafenib in cholangicarcinoma have been
reported so far. LaRocca et al (2007) have reported a long-lasting
stable disease in two patients with advanced cholangiocarcinoma.
El-Khoureiry et al have studied sorafenib as first-line treatment
in advanced and metastatic gallbladder and cholangiocarcinoma
in a phase II trial. They reported a disease control rate of 35%
with a median time to progression and a median OS of 2 and 6
months, respectively; grade 3–4 toxicities were observed in 20
patients (66.7%), and 1 patient died because of cardiovascular
toxicity (El-Khoureiry et al, 2007). These data, as well as our data,
show that the activity of sorafenib as a single agent is marginal
compared with systemic chemotherapies using gemcitabine and
cisplatin; moreover, patients with very good performance status
may benefit from this treatment.
The toxicity profile of sorafenib in our trial was slightly different
from that reported by Llovet et al (2008a)in patients with
hepatocellular carcinoma treated with sorafenib. In particular, we
observed more frequent skin rash (35 vs 16%), liver toxicity (6.5 vs
o1%), and fatigue (33 vs 22%). Moreover, five patients experi-
enced vascular toxicity: DVT in three patients and pulmonary
embolism in two patients. These toxicities were not observed in the
SHARP study. A possible explanation for the higher occurrence
of toxicity in our trial can be the inclusion of patients who
had received previous treatment for advanced disease (54% of
the patients were pretreated with chemotherapy). However, the
safety profile of sorafenib in our trial is acceptable in comparison
with that observed in patients treated with chemotherapy. Several
phase II clinical trials of gemcitabine plus cisplatin in advanced
biliary tract carcinoma reported a grade 3–4 toxicity in the range
of 33–75% (Thongprasert et al, 2005; Iyer et al, 2007; Meyerhardt
et al, 2008).
Very few data are available on the combination of sorafenib
with chemotherapeutic agents. Promising results have been reported
with the combination of sorafenib with carboplatin and paclitaxel in
melanoma and ovarian cancer, with oxaliplatin in gastric and
colorectal cancer, and with capecitabine in different solid tumours
(Takimoto and Awada, 2008). Although a direct comparison between
the combination of sorafenib plus chemotherapy vs single agent is
limited, a recent comprehensive review showed that a combination of
sorafenib with cytotoxic agents is generally well tolerated (Takimoto
and Awada, 2008). Moreover, the toxicity profiles observed in
combination trials indicate that toxicities associated with sorafenib
rarely overlap with those induced by chemotherapy (Dal Lago et al,
2008; Takimoto and Awada, 2008). Finally, bevacizumab, a humanised
anti-VEGF-A monoclonal antibody, has been tested in patients with
biliary tract cancer, in combination with gemcitabine and oxaiplatin,
in a phase II trial. A total of 19 patients have been treated with a partial
response rate of 15.8% and with a stable disease rate of 26.3% (Clark
et al, 2007). Other anti-angiogenic agents including vandetanib and
cediranib are currently under evaluation in ongoing clinical trials.
In conclusion, our study shows that sorafenib has a low activity
in cholangiocarcinoma. However, patients having a very good
performance status may experience some benefit. In future studies,
a combination of sorafenib with cytotoxic drugs could be tested.
Correlative studies to define predictive molecular markers for
sorafenib should be undertaken.
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